China Pharma Univ. IDO1 compound 4t

China Pharma Univ. IDO1 compound 4t: sourced facts only. name: "Herein, we describe the discovery of compound 4t, the first inhibitor targeting both IDO1/2 that has excellent in vitro inhibitory activity (IDO1 IC50 = 28 nM and IDO2 IC50 = 144 nM)." [PMID:34854662]; target: "Herein, we describe the discovery of compound 4t, the first inhibitor targeting both IDO1/2 that has excellent in vitro inhibitory activity (IDO1 IC50 = 28 nM and IDO2 IC50 = 144 nM)." [PMID:34854662]; developer: "State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China." [PMID:34854662]; stage: "Notably, 4t (TGI = 69.7%) exhibited significantly stronger in vivo antitumor potency than epacadostat (TGI = 49.4%) in CT26 xenograft mouse models, highlighting the advantages of IDO1/2 dual inhibitors for tumor immunotherapy." [PMID:34854662]